Bookmark

Add to MyYahoo RSS

Johnson and Johnson News

News on Johnson and Johnson (Ticker: JNJ) continually updated from thousands of sources around the net.

2 hrs ago | ComputerWorld

Paging Dr. Watson, IBM's medical adviser for the future

IBM continues to make the case for the nascent field of cognitive computing, showing off some Watson prototypes Thursday that could help speed scientific discovery in the medical field, by scanning large volumes of literature and data far more quickly then humans can, and suggesting possible leads.

Comment?

Related Topix: Science, Computer Science, Healthcare Law, Law, Johnson & Johnson, Biotech, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry

3 hrs ago | TheStreet.com

Why Johnson & Johnson (JNJ) Stock Is Declining Today

Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 8+ You may proceed to the site by clicking here , however some pages might not work correctly.

Comment?

Related Topix: Johnson & Johnson, Biotech, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, Advanced Transit Dynamics, VisionCare Ophthalmic Technologies, Startups, Johnson Controls

7 hrs ago | Reuters

FDA says Johnson & Johnson recalls some jaw implants

Johnson & Johnson is recalling some lots of its implant used to correct defects of the jaw following more than a dozen cases of injury.

Comment?

Related Topix: Johnson & Johnson, Biotech, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, Food and Drug Administration, DePuy Orthopaedics, Medical Equipment, Hospital Administration, St Peters Health Care Services

7 hrs ago | CBC News

Jaw implants recalled

Johnson & Johnson is recalling some lots of its implant used to correct defects of the jaw, following more than a dozen cases of injury.

Comment?

Related Topix: Johnson & Johnson, Biotech, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, Startups, Acclarent, DePuy Orthopaedics, Medical Equipment, Hospital Administration, St Peters Health Care Services

7 hrs ago | The Motley Fool

Bristol-Myers Squibb's Daklinza Threatens Johnson & Johnson More Than Gilead Sciences

Europe had already shown its willingness to support the use of daclatasvir, which will be sold under the brand name Daklinza, when it gave the OK for its compassionate use program last fall.

Comment?

Related Topix: Johnson & Johnson, Biotech, Medicine, Healthcare Industry, Gilead Sciences

11 hrs ago | Heraldseries.co.uk

Service sector firms have helped boost Oxfordshire recovery

The county's economy grew by 3.5 per cent last year, compared with the national rate of 3.2 per cent, making it the second-best-performing area in the south east.

Comment?

Related Topix: Johnson & Johnson, Biotech, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, Outsourcing

15 hrs ago | TheStreet.com

Frustrating Boston Scientific Is Not What the Investor Ordered

The shares peaked in January at $14.08 and have grossly underperformed its peers ever since.

Comment?

Related Topix: Johnson & Johnson, Biotech, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, Startups, Acclarent, DePuy Orthopaedics, Medical Equipment, Hospital Administration, St Peters Health Care Services

Wed Aug 27, 2014

The Verona-Cedar Grove Times

J&J leads companies honing message to filter job applicants

New Brunswick-based Johnson & Johnson wants to hire workers. What it doesn't want is a flood of applicants taking a flier in a tough job market, a common occurrence in the aftermath of the recession.

Comment?

Related Topix: Food, J and J Snack Foods, Johnson & Johnson, Biotech, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, Startups, Acclarent, Micrus

Reuters

IBM launches Watson system for research, hopes for breakthroughs

International Business Machines Corp on Wednesday launched a computer system that can quickly identify patterns in massive amounts of data, an ability that IBM said should hasten breakthroughs in science and medical research.

Comment?

Related Topix: IBM, Johnson & Johnson, Biotech, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry

Seeking Alpha

Can You Live Off Of Dividend Growth Income In Retirement?

I recently had a prospective client come to me with an interesting case. He and his wife have $800,000 saved, half of which is in an IRA.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

Investopedia

Who are Amgen Inc.'s (AMGN) main competitors?

Biotech giant Amgen Inc bills itself as one of the first biotechnology firms. It was founded in 1980 and has grown into a firm with 20,000 employees, a market capitalization of nearly $100 billion, and approximately $20 billion in annual sales.

Comment?

Related Topix: Biotech, Medicine, Amgen, Healthcare Industry, Science / Technology, Johnson & Johnson, Johnson and Johnson Merck Consumer Pharmaceuticals

Tue Aug 26, 2014

WebWire

ViaCyte, Inc. Announces Signing of Rights Agreement with Janssen Research & Development LLC.

ViaCyte, Inc., a privately held regenerative medicine company announced that it has entered into a Rights Agreement with Janssen Research & Development LLC , one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Comment?

Related Topix: Johnson & Johnson, Biotech, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, VisionCare Ophthalmic Technologies, Startups, Scios, OrthoClinical Diagnostics, Medical Equipment

Bioscience Technology

Vivus acquires patent rights to Qsymia ingredient

Vivus has acquired a group of patents covering one of the main ingredients behind its weight loss drug Qsymia from Janssen Pharmaceuticals.

Comment?

Related Topix: Startups, VIVUS, Johnson & Johnson, Biotech, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, Scios

Seeking Alpha

Gilead: Earnings Forecast Justifies $140 Price Target

I have been recommending Gilead for the past 3 years, and for the past 2 years my price target has been $140.

Comment?

Related Topix: Biotech, Gilead Sciences, Healthcare Industry

Seeking Alpha

Merck Collaboration Could Add $150M To Advaxis' Present Value

At ~4.00/share the stock could see an upside of 200% with a target price of $12.90/share on a fully diluted basis according to my fair value.

Comment?

Related Topix: Biotech, Medicine, ImClone Systems, Healthcare Industry, Healthcare Law, Law, Cancer, Health, Cervical Cancer, Prostate Cancer

Mon Aug 25, 2014

Benzinga

The 4 Companies Teaming Up For A New Tool To Fight Cancer

Big pharma and one relatively small company are teaming up to develop a master test that will help doctors pick a combination of drugs tailored to the individual patient's condition.

Comment?

Related Topix: Biotech, SanofiSynthlabo, Medicine, Cancer, Health, Healthcare Industry, Genetics, Veracode, Scientific Instruments, Illumina

GuruFocus.com

Here's Why Johnson & Johnson Is a Good Investment at 52-Week Highs

Johnson & Johnson is appreciating a decent time in 2014, liking 10% and beating the more extensive market so far.

Comment?

Related Topix: Johnson & Johnson, Biotech, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, VisionCare Ophthalmic Technologies, Startups, Scios, OrthoClinical Diagnostics, Medical Equipment

Pharmaceutical Processing

Cilag GmbH International Acquires Covagen AG

Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has acquired Covagen AG, a privately-held, biopharmaceutical company specializing in the development of multispecific protein therapeutics through the FynomAb technology platform.

Comment?

Related Topix: Johnson & Johnson, Biotech, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, Advanced Transit Dynamics, VisionCare Ophthalmic Technologies, Startups, Johnson Controls

Sat Aug 23, 2014

The San Diego Union-Tribune

Viacyte Partners with Janssen on Diabetes Therapy

San Diego's ViaCyte has received $20 million from a drug company to advance its stem cell-based therapy for Type 1 diabetes into human clinical trials.

Comment?

Related Topix: Medicine, Diabetes, Health, Stem Cell Research, Science / Technology, Johnson & Johnson, Biotech, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry

PR-inside.com

New market study, "McNeil Iberica SLU in Consumer Health (Spain)", has been published

However, during 2013 the company showed a much lower profile in terms of new launches and television campaigns.

Comment?

Related Topix: Euromonitor International, Advertising, Johnson & Johnson, Biotech, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, Nutrition

•••
•••
•••
•••
•••

Ashburn Jobs

•••
•••
•••
•••